225 related articles for article (PubMed ID: 30418820)
1. Will direct oral anticoagulants completely replace warfarin?
Thachil J
Br J Hosp Med (Lond); 2018 Nov; 79(11):604-605. PubMed ID: 30418820
[No Abstract] [Full Text] [Related]
2. Oral anticoagulants for Asian patients with atrial fibrillation.
Sabir I; Khavandi K; Brownrigg J; Camm AJ
Nat Rev Cardiol; 2014 May; 11(5):290-303. PubMed ID: 24614113
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Juhlin T
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512137
[No Abstract] [Full Text] [Related]
4. Stroke prevention in atrial fibrillation: another step sideways.
Go AS; Singer DE
Lancet; 2008 Jan; 371(9609):278-80. PubMed ID: 18294981
[No Abstract] [Full Text] [Related]
5. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
Hylek EM
Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
[No Abstract] [Full Text] [Related]
6. Dabigatran in clinical practice.
Nagarakanti R; Ellis CR
Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
[TBL] [Abstract][Full Text] [Related]
7. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Alamneh EA; Chalmers L; Bereznicki LR
Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
9. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
[TBL] [Abstract][Full Text] [Related]
10. Warfarin for stroke prevention in atrial fibrillation: time to switch?
Ahmad Y; Lip GY
Int J Clin Pract; 2013 Jul; 67(7):603-5. PubMed ID: 23758442
[No Abstract] [Full Text] [Related]
11. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Waks JW; Zimetbaum PJ
Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
[TBL] [Abstract][Full Text] [Related]
12. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants.
Turagam MK; Velagapudi P; Flaker GC
Clin Interv Aging; 2015; 10():1431-44. PubMed ID: 26366064
[TBL] [Abstract][Full Text] [Related]
13. [Treatment with oral anticoagulants in older patients: Should warfarin still be prescribed?].
Lafuente-Lafuente C; Oasi C; Belmin J
Presse Med; 2019 Feb; 48(2):154-164. PubMed ID: 30528147
[TBL] [Abstract][Full Text] [Related]
14. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
16. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Kasmeridis C; Lip GY; Apostolakis S
Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
[TBL] [Abstract][Full Text] [Related]
17. New oral anticoagulants in elderly patients with atrial fibrillation.
Deedwania PC
Am J Med; 2013 Apr; 126(4):289-96. PubMed ID: 23369212
[TBL] [Abstract][Full Text] [Related]
18. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
Alcocer L
Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
[TBL] [Abstract][Full Text] [Related]
19. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.
Kozlowski D; Budrejko S; Raczak G; Rysz J; Banach M
Curr Pharm Des; 2013; 19(21):3816-26. PubMed ID: 23286429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
